Results 141 to 150 of about 2,874,295 (194)

Epsilon Aminocaproic Acid — A Dangerous Weapon

New England Journal of Medicine, 1969
Of the body's defenses against injury, the proteolytic activity of plasmin, an enzyme that can evolve in plasma from an inert precursor, plasminogen, is most intriguing. Clinical attention has been centered upon the digestion of fibrin by plasmin, but this enzyme also digests other clotting factors, converts the first component of complement to its ...
Oscar Ratnoff, O D Ratnoff
exaly   +3 more sources

Reduction of Postprostatectomy Bleeding by Epsilon-Aminocaproic Acid

New England Journal of Medicine, 1962
EPSILON-aminocaproic acid (EACA) is a potent inhibitor of plasminogen activation in relatively low concentrations (5 × 10–4M) and of plasmin at considerably higher concentrations (1 × 10–2M).1 , 2 This drug, first described by Japanese investigators, has the structural formula: Clinical studies have indicated that it is effective in hemorrhagic ...
Perry B Hudson, Theodore H Spaet, P B Hudson   +2 more
exaly   +3 more sources

Epsilon-Aminocaproic Acid in Hæmaturia

Lancet, The, 1975
D T Purtilo, Davidt Purtilo
exaly   +2 more sources

Inhibition of Ejaculation Due to Epsilon Aminocaproic Acid

New England Journal of Medicine, 1978
B E, Evans, L M, Aledort
exaly   +3 more sources

Epsilon-Aminocaproic Acid (EACA)

Seminars in Thrombosis and Hemostasis, 2008
Epsilon-aminocaproic acid (EACA) is a synthetic inhibitor of the plasmin-plasminogen system. It is the only potent antifibrinolytic agent which is commercially available in the United States. Effective blood levels of the drug are readily obtainable with either oral or intravenous administration, with very high levels of the drug being found in the ...
J D, Griffin, L, Ellman
openaire   +2 more sources

Rhabdomyolysis Induced by Epsilon-Aminocaproic Acid

Annals of Pharmacotherapy, 1997
OBJECTIVE: To report a case of rhabdomyolysis associated with epsilon-aminocaproic acid (epsilon-ACA). CASE SUMMARY: A 33-year-old female patient with chronic granulocytic leukemia was treated with epsilon-ACA for approximately 3.5 ...
B D, Seymour, M, Rubinger
openaire   +2 more sources

Thrombosis with Epsilon Aminocaproic Acid Therapy

American Journal of Clinical Pathology, 1971
A patient with postoperative bleeding was treated with epsilon aminocaproic acid (EACA). Subsequent coagulation studies supported the diagnosis of intravascular coagulation and the patient subsequently developed renal failure due to glomerular thromboses.
H R, Gralnick, P, Greipp
openaire   +2 more sources

Epsilon-Aminocaproic Acid Has No Association With Thromboembolic Complications, Renal Failure, or Mortality After Liver Transplantation

Journal of Cardiothoracic and Vascular Anesthesia, 2016
Objectives: To examine the role of epsilon-aminocaproic acid (EACA) administered after reperfusion of the donor liver in the incidences of thromboembolic events and acute kidney injury within 30 days after orthotopic liver transplantation.
Ramona Nicolau-Raducu, Joseph R Koveleskie, Bobby Nossaman   +2 more
exaly   +2 more sources

Comparison of Intraoperative Tranexamic Acid and Epsilon-Aminocaproic Acid in Cardiopulmonary Bypass Patients

JTCVS Open, 2020
OBJECTIVE: To compare tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) in patients undergoing cardiac surgery with cardiopulmonary bypass. METHODS: Over a consecutive 2-year period, 824 adult cardiac surgery patients who received TXA during an ...
Michael P Robich, Joseph Rappold, Robert S Kramer   +2 more
exaly   +1 more source

Epsilon-Aminocaproic Acid Myopathy

European Neurology, 2008
A case of acute necrotic myopathy due to epsilon-aminocaproic acid (EACA) is described and compared with similar cases in the literature. This myopathy has only been noted after prolonged administration of the drug. The pathogenesis of this necrotic myopathy remains unclear, but our findings did not support a muscular vasculitis or an autoimmune ...
J.A.L. Vanneste, G.K. van Wijngaarden
openaire   +1 more source